Self-Management Maintenance Inhalation Therapy With eHealth (SELFIE): Observational Study on the Use of an Electronic Monitoring Device in Respiratory Patient Care and Research by Kuipers, E. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/204620
 
 
 
Please be advised that this information was generated on 2019-07-12 and may be subject to
change.
Original Paper
Self-Management Maintenance Inhalation Therapy With eHealth
(SELFIE): Observational Study on the Use of an Electronic
Monitoring Device in Respiratory Patient Care and Research
Esther Kuipers1,2, PharmD; Charlotte C Poot3, MSc; Michel Wensing1,4, PhD; Niels H Chavannes3, PhD; Peter AGM
de Smet1,5, PhD; Martina Teichert6, PhD
1Department of IQ Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, Netherlands
2BENU Apotheek Zeist West, Zeist, Netherlands
3Department of Public Health and Primary Care, Leiden University Medical Centre, Leiden, Netherlands
4Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany
5Department of Clinical Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, Netherlands
6Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre, Leiden, Netherlands
Corresponding Author:
Esther Kuipers, PharmD
Department of IQ Healthcare
Radboud Institute for Health Sciences
Radboud University Medical Centre
PO Box 9101
Nijmegen, 6500HB
Netherlands
Phone: 31 243610591
Fax: 31 243540166
Email: esther.kuipers@radboudumc.nl
Abstract
Background: Electronic inhalation monitoring devices (EIMDs) are available to remind patients with respiratory diseases to
take their medication and register inhalations for feedback to patients and health care providers as well as for data collection in
research settings.
Objective: This study aimed to assess the validity as well as the patient-reported usability and acceptability of an EIMD.
Methods: This observational study planned to include 21 community pharmacies in the Netherlands. Patient-reported inhalations
were collected and compared to EIMD registrations to evaluate the positive predictive value of these registrations as actual patient
inhalations. Patients received questionnaires on their experiences and acceptance.
Results: A convenience sample of 32 patients was included from across 18 pharmacies, and 932 medication doses were validated.
Of these, 796 registrations matched with patient-reported use (true-positive, 85.4%), and 33 inhalation registrations did not match
with patient-reported use (false-positive, 3.5%). The positive predictive value was 96.0%, and 103 patient-reported inhalations
were not recorded in the database (false-negative, 11.1%). Overall, patients considered the EIMD to be acceptable and easy to
use, but many hesitated to continue its use. Reminders and motivational messages were not appreciated by all users, and more
user-tailored features in the app were desired.
Conclusions: Patients’ interaction with the device in real-world settings is critical for objective measurement of medication
adherence. The positive predictive value of this EIMD was found to be acceptable. However, patients reported false-negative
registrations and a desire to include more user-tailored features to increase the usability and acceptability of the EIMD.
(J Med Internet Res 2019;21(5):e13551)   doi:10.2196/13551
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Introduction
Electronic monitoring devices are increasingly important in the
self-management of chronic diseases such as chronic obstructive
pulmonary disease and asthma. These two chronic respiratory
diseases affect an estimated 384 and 235 million people
worldwide, respectively [1,2]. According to the prevailing
clinical guidelines, daily intake of inhaled corticosteroids is the
cornerstone for optimal asthma treatment, and inhaled
corticosteroids are also used in chronic obstructive pulmonary
disease, together with bronchodilators [2,3].
An electronic inhalation monitoring device (EIMD), which
measures inhalation actuations, provides detailed data on patient
adherence to treatment for both patient and health care providers
[4-7]. EIMDs, in combination with audiovisual reminders and
feedback, have the potential to improve medication adherence
and health care outcomes by facilitating self-management and
aiding in clinical (shared) decision making [8-15]. Previous
studies have shown that involving patients in monitoring their
own symptoms can lead to improved awareness and competence
in disease management [16].
Besides clinical practice, EIMD data could be used as objective
outcome measures for medication adherence in research [17-19].
The integrated time stamp enables comprehensive data collection
in research populations on the timing and pattern of inhaler
actuation, including dose dumping [20]. This way of data
collection was stated to be more accurate and objective for the
evaluation of medication use and is considered to be superior
to self-report, canister weighing, or pharmacy dispensing data
[17,21].
However, the widespread use of EIMDs for measuring patients’
medication adherence in clinical practice and research setting
depends on the acceptability by patients as well as health care
providers and researchers, respectively. From the perspectives
of both patient care and research, it is important that the EIMD
is accurate and valid [20,22-24]. Earlier in-vitro studies (product
validation studies) evaluating the validity of an EIMD, following
a fixed protocol and simulating inhalations, found 99.2% overall
accuracy of detection [25]. On the contrary, small-scale studies
reported malfunctioning devices and potential loss of data as
well as overrecording of doses that did not reflect actual
inhalations [22-24,26]. Use of EIMDs as objective measures
for medication adherence for research purposes in a real-world
setting depends not only on technical capabilities, but also on
how the user interacts with the system in real life. In other
words, results in laboratory settings might not apply to EIMD
validity and reliability in the broad use by community-dwelling
patients. As EIMDs could be used for measuring real-time
medication adherence in clinical trials, evidence on their
potential to measure patient inhalations in community-dwelling
patients is relevant.
For the implementation of EIMD in clinical practice, it is
important to acknowledge the complexity of the implementation
process, influenced by patients’ acceptance and ability to use
information technology tools [27,28]. Hence, before the EIMD
is implemented and used as an accurate and reliable measure
for patients’ actual medication adherence in a real-world setting
(in both clinical decision making and research), a rigorous
evaluation of the technical performance, usability, and
acceptability in clinical practice is required.
This study aimed to assess the validity and patient-reported
usability and acceptability of an electronic adherence monitor
and reminder device for patient care and research.
Methods
Study Design
This prospective observational study on agreement between
EIMD measurements and patient-reported inhalations was
conducted between April 18 and May 25, 2018.
Setting
This study was conducted by 21 students in the second year of
their master’s program in pharmacy from the University of
Leiden, the Netherlands, during their internships in community
pharmacies. The students were asked to validate EIMD
registrations for two patients each, for 3 weeks, and they
received additional training on the use of the EIMD program.
The individual monitoring of patients was time consuming
because of the protocol-specific information requirements, and
consequently, dedicated persons with enough time were needed
in the pharmacy. Additionally, the acquaintance with an
innovative device to be implemented into daily practice and
individual patient coaching were relevant learning objectives
for the students.
Dutch pharmacists have a professional and legal responsibility
to provide drug treatment for their patients and, as most patients
in the Netherlands attend one community pharmacy, pharmacists
usually possess the complete medication histories of their
patients [29].
Ethics Approval
The study protocol was approved by the Ethical Committee of
the Radboudumc Nijmegen (approval number, 2018-4153).
Written informed consent was obtained from all individual
participants included in this study, prior to the study.
Electronic Monitoring
The EIMD to be assessed was the Turbu+ V2.1 (AstraZeneca
UK Limited), consisting of three components: (1) the electronic
device that could be attached to the inhaler of the corresponding
product “Symbicort Turbuhaler,” (2) an app to be installed on
the patient’s mobile phone, and (3) an online portal allowing
the health care professional access to the same actuation data.
During patient inhalation, the device was actuated and the date
and time of the actuations were recorded. The data were
synchronized with the app on the mobile phone by Bluetooth,
and the app visualized the timeline of these data up to the
previous month. All EIMD data for measured actuations were
automatically and electronically linked to the online portal of
the health care provider for his/her patients and an additional
research database containing the same data but anonymized.
The research database has been setup to study patterns of
medication adherence and to evaluate the effectiveness on
interventions for medication adherence across multiple studies.
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Actuation data from all health care professionals included in
this study were aggregated into one central research database
containing data on all included patients from the participating
pharmacies.
Patients could only use the EIMD program after they were
enrolled and trained by their health care provider. After entering
the name, birth of date, sex, dose regimen settings, and email
address, the patient automatically received an email with the
link to download the app. The time(s) for a pop-up reminder in
the app could be set individually by the patient at the time of
scheduled inhalation(s). If patients did not take their medication,
30 minutes after the scheduled inhalation, a “missed-medication”
motivational message was sent automatically. Patients received
a weekly motivational push notification in the app (eg, “Great
week. You’ve been following your prescription this week! Keep
it up!”).
Patient Inclusion
Patients were eligible to participate if they (1) were current users
of budesonide/formoterol Turbuhaler (Anatomic Therapeutic
Chemical code R03AK07) [30] with at least two prescriptions
in the previous 12 months; (2) were of age ≥ 18 years; (3) were
regular patients in the pharmacy (registered in the pharmacy
system and receiving dispensings from this pharmacy only); (4)
had access to a smartphone, and (5) were able to use the internet.
We aimed to include current users who were familiar with the
inhaler. At random, eligible patients were invited during regular
pharmacy visits or by phone. If interested, patients received an
information leaflet on the study and an informed consent form.
Patients interested in participating were asked to provide
informed consent, allowing the student to collect general data
about gender, age, use of short corticosteroid courses (indicating
exacerbations), and refills from the pharmacy database (to assess
adherence rates). Eligible patients were invited to the pharmacy
for an intake visit.
Intake Visit
During the intake visit, the students provided the patient with
an EIMD and (oral and written) instructions. The patients
attached the device to the inhaler and installed the app during
the visit or at home following the instructions. Additionally, the
students verified the pharmacy’s information collected on drug
use, patient’s refill adherence to inhaled corticosteroids, and the
number of oral corticosteroid courses in the previous year.
Subsequently, the patients completed the Beliefs About
Medicines Questionnaire (BMQ), consisting of two parts: the
BMQ Specific list, which measures perceptions of specific
medicines, and the BMQ General list, which measures general
beliefs about medicines. The BMQ Specific list comprises two
scales—one assessing patients’ beliefs about the necessity of
preventer medication for maintaining present and future health
(Necessity scale) and the other for assessing their concerns about
the potential adverse consequences of using such medication
(Concerns scale) [31,32]. All items were rated on a 5-point
Likert scale, with a range of 5-25 possible scores for both scales.
The students explained that they would call the patients 6 times
within 14-21 days to check on their actual drug intake on the
previous days and agreed on the most suitable days and time to
call. If patients wished to, they were allowed to use a paper
diary.
Accuracy and Patient-Reported Use of the Electronic
Inhalation Monitoring Device: Procedures and
Measures
During the follow-up period of 14-21 days, the students phoned
the patients 6 times to check on their actual drug intake and
EIMD performance from the previous day, and if possible, up
to the day of the earlier phone call. The student collected and
reported information on the number and time of daily
inhalations, and all particularities or other circumstances that
the patient reported were registered by the student in an Excel
file. These were subsequently centralized into one patient
self-reported database.
To avoid socially desirable answers and to collect reliable data,
patients were instructed that this study focused on the accuracy
of the device (instead of their medication use), and they were
asked to use the medication at their usual dose and frequency
and to use only the EIMD prepared device during the study
period and no other inhalers of this medication. Semistructured
questions were used during the phone call; for example, “When
did you use your medication for the last time?” and “Do you
see any registrations in your app that do not represent real
medication use?”
During the phone call, the student had immediate access to the
EIMD data and compared the data from the research database
with the information reported by the patient (and registered in
the patient self-reported database). Any discrepancies were
directly discussed with the patient and registered.
Usability and Acceptability of the Patient Electronic
Inhalation Monitoring Device: Procedures and
Measures
To evaluate patients’ usability, patients received two
questionnaires at the end of the study, including the System
Usability Scale (SUS), which is a validated instrument for
evaluating the usability of a wide range of products and services
[33,34]. The SUS score can range from 0 to 100. For products
with a score less than 70, improvement options should be
considered [34].
The second questionnaire addressed the experiences and
acceptability of the program and the expectations on the
pharmacists’ role in counselling. This part consisted of 12
statements, formulated positively or negatively, measured on a
5-point Likert Scale (1=strongly disagree, 5=strongly agree),
followed by 3 multiple-choice questions regarding the frequency
of using the app and whether the patient would like to continue
the program and by 4 open questions on advantages,
disadvantages, and targets for improvements.
Data Analysis
The main outcome measure was the positive predictive value
(PPV), calculated as (the number of correctly registered doses
according to the patient self-reported database and registered
database)/(the total number of registered doses [true and false
positives])*100. Results of the questionnaires were analyzed
using descriptive statistics. Responses to the open questions
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were coded and summarized for patients’ opinions, wishes, and
barriers encountered using the EIMD program to identify key
topics via the grounded theory approach [35].
Patient-specific characteristics were assessed with the scores
for the BMQ Specific and BMQ General questionnaires,
represented on a continuous scale. The BMQ necessity and
concerns scores were split at the scale midpoints to distinguish
between four subgroups: accepting (high necessity, low
concerns), ambivalent (high necessity, high concerns), skeptical
(low necessity, high concerns), and indifferent (low necessity,
low concerns) [36]. Refill adherence was calculated as the
proportion of days covered in the prior 12 months (due to prior
dispensings up to 15 months).
Results
Patient Demographics and Questionnaire Completion
A total of 32 patients were included by 18 students (Table 1).
In 3 pharmacies, no patients eligible and willing to participate
were available. The mean age of the included patients was 48.1
years (range, 20-69 years), and 17 patients were female (53.1%).
Medication adherence in the previous year calculated from
dispensing data was 81.3%. Most patients used their medication
twice a day (n=26). Three patients (9%) used an additional diary
to note their daily inhalations. Twenty-five patients (78%)
completed the questionnaires and provided individual comments
on the EIMD (Table 2 and Textbox 1).
Table 1. Patient characteristics (N=32).
ValueCharacteristic
48.1 (20-69)Age (years), mean (range)
17 (53.1)Female, n (%)
0.31 (0-4)Number of oral corticosteroid courses in the last year, mean (range)
81.32 (17.53-194.80)Medication adherence in the previous year calculated from dispensing data (n=28), mean % (range)
10.21 (5-16)BMQa General Harm score (n=29; possible range: 4-20), mean (range)
8.04 (4-13)BMQ General Overuse score (n=29; possible range: 4-20), mean (range)
17.70 (10-24)BMQ Specific Necessity score (n=30; possible range: 5-25), mean (range)
10.97 (6-17)BMQ Specific Concerns score (n=30; possible range: 5-25), mean (range)
aBMQ: Beliefs About Medicines Questionnaire.
Table 2. Patients’ acceptability of the Electronic Inhalation Monitoring Device (EIMD) program. Values in italics indicate the highest percentage(s)
per statement.
Agree (score 4-5),
n (%)
Neutral (score 3),
n (%)
Disagree (score 1-2),
n (%)
Statement
11 (44)3 (12)11 (44)The EIMD programme does provide useful insights in my medication usea
11 (44)8 (32)6 (24)The EIMD programme is useful to me
4 (16)2 (8)19 (76)The EIMD programme is time-consuming
4 (16)10 (40)11 (44)The motivational messages in the EIMD app feel positive for me
9 (36)6 (24)10 (40)The reminders of the EIMD programme help me to take my medication in time
10 (40)5 (20)10 (40)The EIMD programme contributes to dealing with my illnessa
7 (28)8 (32)10 (40)The EIMD programme contributes to the interaction with my pharmacist
5 (20)9 (36)11 (44)The EIMD programme helps establishing a habit to use my medication
6 (24)9 (36)10 (40)The EIMD programme gives me confidence to help manage my disease
6 (24)6 (24)13 (52)The pharmacist’s monitoring of my medication use with this programme helps me
to use my medication bettera
18 (72)3 (12)4 (16)When someone can monitor my medication intake, I take my medication as usuala
9 (36)5 (20)11 (44)I see added value of the EIMD programme to manage my medication intakea
6 (24)12 (48)7 (28)I would recommend the EIMD programme to other patients
20 (80)3 (12)2 (8)The pharmacist can play an important role in counselling
aItem was phrased as a negative statement.
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Textbox 1. Selection of patients’ free-text comments about the Electronic Inhalation Monitoring Device program. Values in brackets represent gender
and age of the participants (eg, F24=female, 24 years).
Technical functionalities:
If the app synchronises the data, this may take a long time (maybe this can be improved). In the end, the registration
of my puffs did not go well. [F24]
Until now, the app missed three inhalation registrations in the morning. I clicked twice within a minute, but only one
[inhalation] was registered. [M52]
Patient-technology interaction:
Not all inhalations were registered [in the app on my mobile phone], so I inhaled again and used too much medication.
[F45]
The app is not always working. If medication is taken, this is not always measured. Even if the medication has already
been taken (before the time set), still a reminder was sent. The app does not provide insight into whether the medication
has been taken in the right way. [F20]
The alarm you can set will never go off. So you have no reminder. [F45]
The Turbu+ did not register when the app was [physically] not around, and it was therefore not possible to register
2 inhalations in 1 day. [M55]
The notifications did not work with my Galaxy s7 Edge. [M57]
Patients’ opinions and acceptability of the program:
Regarding the device/app:
The device itself feels rather rickety. The two parts did not really fit together. [M51]
The idea is good, I also see the commercial need, but think about the return for the patient. Information in the app
for how many days medication is still available in the inhaler, would be such convenient return for the patient. For
example, before he goes on holiday, he knows if there are extra medicines needed. [M55]
I feel that tracking medication use can be useful for many patients. However, it remains very difficult, because the
connection of the device and the app is not clear. As a result, it [medication use] is registered at some time, but not
on other times, for unclear reasons. With this, possible useful options of the app will immediately disappear. [M43]
Regarding reminders:
If you are not adherent, the Turbu+ can be convenient as a reminder for using the medication. [F39]
[Useful] when you forget [medication intake] (but I never forget this). [M42]
I personally liked the reminders, and it was also very pleasant that I could monitor myself whether I had taken it or
not! [F24]
I would like to modify the app myself for what I agreed on with my doctor (about minimum and maximum use per
day). [F47]
[I would prefer] a clearer reminder sound signal. [V56]
Regarding motivational messages:
The tone of the written messages deserves carefulness: the patient is the boss, the app only gives advice. [F47]
Regarding attitude to electronic monitoring:
I would only use the app if only I can see it [the data]. Watching by pharmacist should not be the default for each
patient. [F47]
I am intrinsically motivated to use my medication and do not really need an app for that. [M55]
Once the routine is there to take an inhalation twice a day, it has little added value for the users. It gives the impression
that it is only useful for the pharmacist and the manufacturer to collect Big Data. [M55]
I always take my medication when brushing my teeth. So there was no need for help with the intake. In addition, I am
able to feel when I have to use my medication more often, according to my needs. I think that the app can help people
who have difficulties with this. [M28]
[An advantage is] to check when I am not sure about forgotten medicines. Insights into patterns in periods when I
have more symptoms help me to anticipate. [F48]
Thirty patients (94%) completed the BMQ General and Specific
questionnaires at the start of the study. The majority of them
could be classified as acceptant (n=19) regarding their inhalation
medication: 4 patients were ambivalent and 7 were indifferent.
No patients were classified as skeptical.
J Med Internet Res 2019 | vol. 21 | iss. 5 | e13551 | p.5http://www.jmir.org/2019/5/e13551/
(page number not for citation purposes)
Kuipers et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Accuracy and Patient-Reported Use of the Electronic
Inhalation Monitoring Device
Of the 32 patients, 28 completed all 6 phone calls. Overall, the
18 students verified 932 medication doses (mean=29.1 doses
verified per patient; range=3-88). A total of 796 doses registered
in the research database matched patient-reported inhalations
captured in the patient self-reported database (true-positive,
85.41%). In addition, 33 inhalations were registered in the
research database that did not match the actual drug intake, as
reported by the patients in the patient self-reported database
(false-positive, 3.5%). Further, 22 patients reported an average
of 4.7 inhalations (range, 1-20) that were not recorded in the
research database, accounting for a total of 103 inhalations
(false-negative, 11.1%).
Information on registration of 6 of the 32 devices was in full
agreement with the patient-reported inhalations. The PPV of all
registrations in the research database was 96.0%.Some patients
reported technical problems with EIMD data recording and
synchronization of the EIMD data with their mobile phone.
Delayed data synchronization resulted in two patients taking
more medication than prescribed under the assumption that they
had forgotten their dose.
Usability and Acceptability of the Electronic Inhalation
Monitoring Device
The majority of patients indicated that the app was easy to use
and not unnecessarily complex; the mean SUS score was 68.9
(SD 11.34; range, 52.5-90).
In the acceptability questionnaire, patients rated the EIMD
generally as useful (76% neutral or agree) and 84% rated the
EIMD program as not time-consuming (Table 2). With regard
to recommending the EIMD to other patients, the majority rated
this item as neutral (n=12, 48%). In addition, 80% of the patients
indicated that they were not willing (n=15) or uncertain
(“maybe,” n=5) about continuing the program themselves, and
70% (n=14) of these patients reported that they had only
participated in this study because they wanted to help the
students fulfil their assignment and facilitate the research. The
five patients who were positive about continuation reported that
they participated mainly to gain personal insight into their
inhalation patterns. The patients generally felt positive about
the pharmacists’ role in counselling.
Written feedback on the advantages, disadvantages, and targets
for improvements was provided by 25 patients. This feedback
was clustered into four themes: EIMD functionality, reminders,
motivational messages, and attitude toward electronic
monitoring (Textbox 1).
Some of the previously mentioned technical issues reported by
some patients resulted in a level of frustration or confusion
because of missed or unnecessary reminders due to missing
data, which impacted their acceptance of the app (Textbox 1).
The reminders and motivational messages were appreciated by
9 and 4 patients, respectively. Several patients suggested more
individualization of the settings in the app, such as inclusion of
a personal choice to share data with a specific health care
provider and management of their dose regimen settings.
Discussion
Principal Findings
In this study, we found an acceptable PPV: 96.0% of the
registered doses represented patient-reported drug intake.
However, we found a high number of false-negative
registrations: 11.1% of patient-reported inhalations were not
recorded by the EIMD.
These unrecorded patient-reported inhalations could have been
the result of a number of factors, either technical or user-related
issues, that should be discussed. Although in earlier studies,
loss of data or missing data were associated with technical issues
such as battery drain, this was not likely to have occurred during
the short duration of our study [7,24,26]. The high number of
false-negative registrations could possibly be the result of
overreporting by the patients or suboptimal use of the device
(eg, Bluetooth not activated, EIMD not paired to the phone, or
EIMD not within a 5-meter distance from the phone during
inhaler actuation). Assessment of user experience revealed that
the written instruction did not contain detailed information about
the data synchronization protocol, which, combined with
instructions at enrolment, may have led to some of the reported
observations. In earlier research with the same EIMD, the
researchers had presumed the possibility of false-negative as
well as false-positive registrations, but they were unable to
verify the registrations by patients’ actual inhalations or the data
on user interaction with the system to interpret their findings
[15].
This study demonstrated the importance of validating medication
adherence data in real-world settings. Patients’ interaction with
the device is critical for objective measurement of medication
adherence in research and clinical settings. We emphasized on
the importance of evaluating technical performance to identify
technical/user issues and stressed the need of evaluating usability
and acceptability across multiple components of the EIMD.
Previous studies on EIMD performance focused on accuracy
and reliability in laboratory settings and lacked data collected
in a real-life setting where patients interact with the EIMD.
Furthermore, previous studies did not access patient acceptability
and user experience [7,20,23,24,26,37,38], both of which are
essential for successful implementation and sustained use in
daily practice [39]. This is the first study to demonstrate the
importance of evaluating and validating EIMDs in a real-world
setting. The accuracy of inhalation measurement is essential
from not only a research point of view, but also a clinical
perspective, as false-negative registrations lead to unnecessary
signals and reminder messages. Furthermore, it falsely reports
patients as nonadherent, and this could lead to underestimation
of adherence, incorrect clinical decision making, and overuse
of medication when patients assume to have forgotten their
dose.
Patient Experiences and Acceptability of the Electronic
Inhalation Monitoring Device
Our findings on acceptability and user experiences further
underline the importance of evaluating EIMDs on acceptability,
preferably early in the implementation process. There is a
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growing body of evidence on electronic health apps, in general,
that do not perform as expected in clinical practice, because the
app turns out to be unacceptable or does not fit the users’ needs
[40-43]. Although patients indicated that the app was easy to
use and not complex, the majority did not intend to use the app
in the future, apparently because there was no clear personal
need to use the EIMD. They were primarily motivated to use
the EIMD to facilitate the research rather than having an intrinsic
motivation to gain personal insights into their inhalation patterns,
and their medication adherence in the previous year calculated
from dispensing data was already high. Patients with intrinsic
motivation to improve their disease management (eg, based on
low adherence or impaired disease control) would possibly
benefit more from the EIMD. Therefore, understanding different
types of patient segments is important to succeed in the
implementation; the EIMD needs to match with the patient
profile (eg, adherence and asthma control), needs, and
preferences. In addition, the fact that the majority of patients
did not intend to continue with the EIMD may have been the
result of a suboptimal technical performance, for example, loss
or troubles with the Bluetooth connection, which was regularly
experienced; delay in the synchronization of data from the EIMD
to the mobile app; and inhalations taken just before midnight
not visible on the intended day. These technicalities can probably
easily be improved and thereby increase the chance of
acceptance and successful implementation. Moreover, health
care providers and patients would benefit from further
development of the EIMD, so that it can not only detect inhaler
actuation, but also check the inhalation quality, breath force,
and inhalation technique.
Our findings emphasized the need for clear patient selection
and a more individualized, tailored device. In this study, half
of the people found the reminders helpful in taking the
medication on time, while the other half found them useless.
We found similar results for the motivational messages. Hence,
when designing a self-management intervention containing
multiple self-management strategies (ie, motivational messaging,
reminders, and audio-visual behavioral feedback), it is important
to critically review each component on usability separately and
preferably tailor the intervention to the needs of the patient.
Strengths and Limitations
This study has some limitations. First, the actual inhalations
were self-reported by the patients, which could have led to bias
by overreporting actual use (and thus also an overestimation of
unrecorded actuations), as patients might tend to provide socially
desirable answers. However, as a 24-hour patient observation
was not feasible, this was the best way to collect data on
patients’ actual drug intake within this setting. To prevent
socially desirable answers, patients were instructed at the intake
that this study was on verifying the registrations of the EIMD
rather than their medication use or adherence, and during the
phone calls, the students asked open questions. Additionally,
patients were questioned about their actual inhalation mainly
at the same and previous days, with a maximum of 5 days prior.
Thus, the phone calls for data evaluation focused on the most
recent moments of drug intake in order to reduce possible recall
bias. In further analysis regarding the possible impact of recall
bias, we did not observe any differences between measurements
on day 5 and those on the earlier days, or between different age
groups (data not shown). As earlier studies have shown that
there is considerable variation in the accuracy of diaries to note
medication intake [44], the use of a diary was not mandatory.
As patients frequently reported technical issues as a possible
explanation for both missing and extra registered inhalations,
we do not expect much bias from this setting.
Second, all pharmacies were related to the master’s education
program of pharmacy from the University of Leiden. Data were
collected in different pharmacies and by different students, to
prevent bias from specific settings. However, such bias could
not be fully excluded. Although the students were not yet
registered health care providers, they were quite motivated and
technically skillful. The students selected a convenience sample
of patients, although it seemed difficult to find patients with the
original inhalation medication that was fit for the EIMD; in
some pharmacies, no patients could be selected at all. Third,
the short inclusion time of this study, due to the internship
period, could have led to selection of patients who were more
willing to help the students with their task rather than being
interested in their own medication performance or adherence.
This was reflected in patients’ individual comments: They
regularly indicated that the program could be especially useful
for other patients, but that it was of little value to them. Some
patients reported that they did not need “help with the
inhalation” or “an app for taking the medication.” With a mean
medication adherence of >80%, this seems to be a group with
relatively high adherence and could indicate selection bias of
the more adherent patients, for which the device may be less
useful. Further research is needed on how health care providers
should preselect patients for an EIMD on the basis of their
experiences.
A strength of this study was the intensive follow-up from
students, with more than 900 validated measurements. Although
the number of included patients was limited, the number of drug
intake comparisons was sufficient to detect omissions in the
recorded actuations. However, the small population may have
affected the representativeness of the results of the acceptability
questionnaire. The statements in this questionnaire were
formulated positively or negatively to reduce the risk of
positively biased answers. This questionnaire was adapted to
this specific EIMD and not validated beforehand. As a
consequence, some patients might have experienced difficulties
in comprehending the language used or the variety in both
positively and negatively formulated questions.
Implications for the Future
It is recommended that the discussed technical issues should be
further elucidated and solved before using EIMD data as an
objective adherence measurement, and medication overuse may
also be of interest. In order to fully benefit from the EIMD and
guarantee reliability and validity, an EIMD should be validated
in a setting where the users interact with the system and can
encounter technical or user issues. Furthermore, EIMDs and
the accompanying self-management program should be
evaluated on usability in daily practice. This study provided an
example of how to do this. Validation of EIMDs in real-world
settings is likely to improve usability in daily practice; the EIMD
J Med Internet Res 2019 | vol. 21 | iss. 5 | e13551 | p.7http://www.jmir.org/2019/5/e13551/
(page number not for citation purposes)
Kuipers et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
should be easy to use and measure all actuations correctly, even
when the patient is not technically skilled. Future research
should pay sufficient attention to different types of patient
segments, as the EIMD needs to match with the patient profile
(eg, adherence and asthma control), needs, and preferences.
Conclusions
Comparison of EIMD data with patient-reported inhalations
showed that EIMD registrations represented patient inhalations
to an acceptable degree, with a PPV of 96%, but these
registrations were likely to underreport actual drug intake by
11%. Technical improvements should address the Bluetooth
connection and data synchronization. Additionally, patient
characteristics contribute to the validity of EIMD measurements,
and larger sample sizes are needed to explore their influence.
For the acceptance of a self-management program with an
EIMD, patients who benefit from self-monitoring and reminders
should be targeted by tailoring the possibilities to the needs of
the individual user.
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